Axitinib fails as an adjuvant therapy for high risk kidney cancer
The phase 3 ATLAS clinical trial to assess axitinib as [...]
The phase 3 ATLAS clinical trial to assess axitinib as [...]
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]
Data from a recent phase 1b study has shown that [...]
The immunotherapy drug avelumab (Bavencio) has been designated a breakthrough [...]
The following article is a good review of the data [...]
This article, published in UroToday this week, is a nice summary [...]
Results from a phase I clinical trial with a combination [...]
The following video from Practice Update is an interview with [...]
The development of dalantercept, an anaplastic lymphoma kinase 1 (ALK1) [...]